# OnCo record met (target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/targets/met/>
  a schema:BioChemEntity ;
  onco:kind "target" ;
  schema:identifier "met" ;
  schema:name "MET"@en ;
  schema:description "A receptor that is either mutated in some lung cancers or amplified as an escape route when other lung cancer drugs fail."@en ;
  schema:url <https://onco.cc/targets/met/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/C-Met>, <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7029>, <https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105976>, <https://www.uniprot.org/uniprotkb/P08581/entry>, <https://www.ncbi.nlm.nih.gov/gene/4233> ;
  schema:citation <https://en.wikipedia.org/wiki/C-Met> ;
  onco:tag "driver", "kinase", "adc-target" ;
  schema:alternateName "MET" ;
  onco:targetClass "kinase" ;
  onco:firstDescribed "1985"^^xsd:gYear ;
  onco:related <https://onco.cc/biomarkers/met-ex14/>, <https://onco.cc/biomarkers/met-amplification-readout/>, <https://onco.cc/biomarkers/met-overexpression/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/rcc/> ;
  onco:drugs <https://onco.cc/drugs/guardant360-cdx/>, <https://onco.cc/drugs/zanzalintinib/>, <https://onco.cc/drugs/lam561/>, <https://onco.cc/drugs/bezuclastinib/>, <https://onco.cc/drugs/al2846/>, <https://onco.cc/drugs/hs-20117/>, <https://onco.cc/drugs/mcla-129/>, <https://onco.cc/drugs/tqb6411/>, <https://onco.cc/drugs/tqb2922/>, <https://onco.cc/drugs/hdm2017/>, <https://onco.cc/drugs/js111/> ;
  onco:companies <https://onco.cc/companies/imagene-ai/>, <https://onco.cc/companies/lucence/>, <https://onco.cc/companies/mythic-therapeutics/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/hepatocellular-carcinoma-signalling/>, <https://onco.cc/pathways/nsclc-signalling/>, <https://onco.cc/pathways/renal-cell-carcinoma-signalling/> ;
  onco:terms <https://onco.cc/terms/met-exon-14-skipping/>, <https://onco.cc/terms/met-amplification/> ;
  onco:trials <https://onco.cc/trials/nct07439094/>, <https://onco.cc/trials/nct06669117/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-awad-met-exon-14-mutations-lung-jco-2016/>, <https://onco.cc/key-papers/paper-tcga-lung-adenocarcinoma-nature-2014/>, <https://onco.cc/key-papers/paper-frampton-met-exon-14-cancer-discov-2015/>, <https://onco.cc/key-papers/paper-lindeman-lung-molecular-testing-guideline-jto-2018/>, <https://onco.cc/key-papers/paper-kris-lung-cancer-mutation-consortium-jama-2014/>, <https://onco.cc/key-papers/paper-engelman-met-amplification-gefitinib-resistance-science-2007/> .